VIRACLEAN® Leads the Way with a SARS-C0V-2 (COVID-19) Approved Label Claim

• Share article:
• 
• 
• 

Following recent changes to the Guidelines for Disinfectants under Therapeutic Goods Order 104, Whiteley Corporation can confirm VIRACLEAN® has the first newly approved label claim for killing the SARS-CoV-2 (COVID-19) virus on contaminated hospital surfaces.  

NBN News Feature 5 March 2020

• Share article:
• 
• 
• 

Whiteley Corporation is a global leader in infection prevention and is focused on preventing the spread of Covid-19.

“We’re supplying far beyond our normal expectations for these primary infection prevention products including the alcohol-based handrubs, with both healthcare and general applications as well as our surface disinfectant and sterilant products.” – Greg Whiteley, Chairman Whiteley Corporation.

See the latest story featured on NBN news.

The risk of infection via surfaces

• Share article:
• 
• 
• 

A lot of our customers are concerned about the risk of transmission of new Coronavirus (2019-nCoV) via a contaminated surface. Many viruses cannot live for long outside a human or animal host, whereas other viruses can survive for prolonged periods on contaminated surfaces. Based on current information, this Coronavirus (2019-nCoV ) sits somewhere in the middle of the risk zone. It can survive on a contaminated surface, but probably not for long. Thorough surface cleaning and disinfecting will ensure that any potentially contaminated surface is left in a clean and hygienic condition.

Whiteley Corporation has conducted a huge number of disinfectant tests against a wide array of infectious viruses over the past twenty-five years. We continue this long history of disinfectant and cleaning research with on-going testing and collaborative research programs, including virucidal testing. This knowledge frames the important factors to note about Coronavirus with respect to disinfectants.

Infection Prevention Insights – COVID 2019 by Professor Mary Lou McLaws

• Share article:
• 
• 
• 

In late December 2019 an outbreak was reported to the World Health Organization (WHO) in Wuhan, China and later identified as a novel coronavirus (2019-nCov). By 28 January 2020 the virus had killed 131 and infected at least 5494 people across 29 provinces. Rapidly, the outbreak became a pandemic with 84 cases in 17 countries including Australia.
  

Cleaning, Disinfection and Hand Hygiene

• Share article:
• 
• 
• 

Facilities including healthcare can be exposed to a range of pathogenic micro-organisms if appropriate infection prevention practices are not in place. These organisms can be transmitted through contact with contaminated objects such as high touch areas including door handles, railings, work stations and telephones. Good hand hygiene practices and surface disinfection are both critical in reducing the spread of infection in large scale work environments.

What can you do to reduce the risk of infection in your facility?

Surface Cleaning & Disinfection

For general cleaning and disinfection and normal additional precautions, we recommend Viraclean® or Surfex®. Both products have proven label kill claims for SARS-Cov-2 (COVID-19). For maximised cleaning and disinfecting efficacy we also recommend using  V-Wipes.

Hand Hygiene

 As per the CDC recommendations above, Healthcare Professionals should perform hand hygiene using Alcohol Based Hand Rub (ABHR) before and after all patient contact, contact with potentially infectious material, and before putting on and upon removal of PPE, including gloves. Hand hygiene in healthcare settings also can be performed by washing with soap and water for at least 20 seconds. If hands are visibly soiled, use soap and water before returning to ABHR.

Whiteley offer a range of hand cleaning products as Dermalux Everyday, Dermalux Natural Hand and Body wash, and Primrose Soap.

Whiteley recommends Bactol® Alcohol Gel, a 70% v/v alcohol-based hand rub approved for use in healthcare. For all non healthcare facilities we recommend Sanitol Antibacterial Hand Sanitiser.

As always please follow directions for use for the appropriate product.

For more information please contact your Whiteley Corporation Sales Representative.

Darran Leyden awarded Certificate of Appreciation from ANZGITA

• Share article:
• 
• 
• 

Whiteley Corporation's Managing Director Darran Leyden was awarded a Certificate of Appreciation from ANZGITA at their recent AGM in September 2019. The ANZGITA board recognises and acknowledges Darran's exemplary commitment over the past few years in supporting ANZGITA's mission.   

Novel Solutions for Biofilm Infections

• Share article:
• 
• 
• 

In early August the first annual review meeting was conducted for the Novel Solutions for the Biofilm Infections research project. This is a collaborative research project between the University of Sydney, Whiteley Corporation and the Innovative Manufacturing Cooperative Research Centre (iMCRC), with an investment of over $4m over four years.  

Hospital cleaning trial cuts infections

• Share article:
• 
• 
• 

 A major trial of a bundle of hospital cleaning practices in 11 Australian hospitals has made significant reductions in healthcare-associated infections and demonstrated cost-benefits. The aim of the study was to investigate whether a change in cleaning practices was effective in reducing the 165,000 healthcare-associated infections in Australia each year. The REACH study was funded by an NHMRC grant (GNT1076006), led by QUT, in partnership with Wesley Medical Research, and several industry partners including Whiteley Corporation.
  

Harmful bacterial biofilms target of new manufacturing research partnership

• Share article:
• 
• 
• 

Healthcare, food production and manufacturing industry to benefit Novel solutions for biofilm infections are the focus of a collaborative research agreement between the University of Sydney, Whiteley Corporation and the Innovative Manufacturing Cooperative Research Centre.
Over four years, $3.5 million will be co-invested in the project by the Innovative Manufacturing Cooperative Research Centre (IMCRC), University of Sydney and medical and industry manufacturer Whiteley Corporation.
The research will be led by Dr Jim Manos and Dr Theerthankar Das from the Central Clinical School’s Discipline of Infectious Diseases and Immunology in the University’s multidisciplinary Charles Perkins Centre, and Dr Trevor Glasbey and Dr Greg Whiteley from the Hunter-based Whiteley Corporation.
Biofilms formed by bacteria on living tissue cause morbidity and mortality in humans and animals. They also form on inanimate medical-related surfaces such as catheters, implants, medical instruments and almost all dry surfaces, where they pose a significant infection risk for patients.   

Hunter Business Innovation Event

• Share article:
• 
• 
• 

Hunter Business Chamber recently held their Hunter Business Innovation event featuring Whiteley Corporation and Hunter Water. Darran Leyden, Managing Director for Whiteley Corporation spoke about the latest research and development projects at Whiteley Corporation highlighting the award winning Innovative product, Surfex.